Candidate for new heart failure and reduced ejection fraction therapy — angiotensin receptor-neprilysin inhibitor (ARNI). Clinician’s guide
Abstract
The European Society of Cardiology (ESC) introduced a new class of drugs — ARNI (angiotensin receptor-neprilysin inhibitor) in patients with heart failure and reduced ejection fraction (HFrEF) (class I, level of evidence B) in the recently published guidelines for heart failure (HF), published in 2016. The only representative of ARNI is sacubitril/valsartan. Based on the results of the PARADAGIM-HF study, sacubitril/valsartan is recommended instead of angiotensin-converting enzyme inhibitors (ACEI) to further reduce the risk of death and hospitalization because of HF in outpatients with stable HFrEF, with symptomatic HF (NYHA II–IV) persist despite optimal treatment with ACEI (or angiotensin II receptor antagonists), beta-adrenolytic and mineralocorticoid receptor antagonist. The paper presents case report of first 2 patients with HFrEF who sacubitril/valsartan therapy was initiated.
Keywords: heart failureangiotensyn II receptor antagonist and neprilysin inhibitorARNI
References
- Niewydolność serca w Polsce — raport 2016. Materiały informacyjne Sekcji Niewydolności Serca PTK. http://www.niewydolnosc-serca.pl/barometr.pdf (9.05.2017).
- Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Sobczak S, Lelonek M. LCZ696 przełomem w leczeniu przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory. Folia Cardiol. 2016; 10(6): 403–409.
- Lelonek M. Niewydolność serca i powtarzające się hospitalizacje. Folia Cardiol. 2016; 11(1): 37–46.
- Entresto™. Charakterystyka Produktu Leczniczego 2015.
- Hussar DA, Abdelsayed M. Sacubitril/valsartan, ivabradine hydrochloride, alirocumab, and evolocumab. J Am Pharm Assoc. 2015; 55(6): 674–678.
- McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
- Farmakis D, Bistola V, Karavidas A, et al. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: current evidence and early experience. Int J Cardiol. 2016; 223: 781–784.
- McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15(9): 1062–1073.
- Desai AS, McMurray JJV, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36(30): 1990–1997.
- Lelonek M. The need to apply the best therapy in heart failure — the era after PARADIGM-HF. Arch Med Sci. https://www.termedia.pl/The-need-to-apply-the-best-therapy-in-heart-failure-the-era-after-PARADIGM-HF,19,27495,1,1.html (9.05.2017).
- Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016; 18(9): 1193–1202.
